Many people who take semaglutide notice that weight loss is steady for several months and then slows or stops, even though they are still taking the medication. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. The question of why it seems to stop working applies to both. This article explains what is known about weight-loss plateaus and what is not.
A plateau is the expected pattern
A plateau is not a sign that something has gone wrong. In the STEP 1 trial of weekly semaglutide in adults with overweight or obesity, participants lost an average of 14.9 percent of body weight over 68 weeks, compared with 2.4 percent for placebo. The trial's published weight curve shows that most of that loss occurred during the first year and that average weight then leveled off rather than continuing to fall. Weight-loss medications move the body toward a new, lower weight.
How the body adapts to weight loss
The best-supported explanation for a plateau is metabolic adaptation. As body weight falls, the body uses less energy at rest. This compensatory decrease in basal metabolic rate is recognized as a factor that limits further weight loss during treatment with incretin medications such as semaglutide. Researchers are now studying ways to raise energy expenditure alongside these medications for this reason.
Appetite hormones adapt as well. In a study of adults who lost weight through a very-low-energy diet, the levels of appetite-regulating hormones still favored hunger a full year after the weight loss, and participants reported more hunger than at the start. That study did not involve a GLP-1 medication, but it shows how strongly the body's hormonal signals favor a return to the previous weight.
What the "resistance" explanation gets wrong
Some online sources attribute apparent resistance to semaglutide to reduced receptor responsiveness or to impaired function of the insulin-producing cells of the pancreas. That explanation is not supported by good evidence. Research on the body's own GLP-1 hormone has shown that its effect on slowing stomach emptying weakens with repeated exposure. That finding concerns stomach emptying in short laboratory studies. It has not been shown to explain why weight levels off during long-term treatment.
Factors worth reviewing with your provider
Because a plateau is expected, the useful question is whether the weight you have reached is a healthy one for you and whether anything else is contributing. A provider may review several practical factors with you.
- Missed or delayed doses can reduce the medication's effect on appetite.
- Some other medications, including certain antidepressants, antipsychotics and steroids, are associated with weight gain.
- Protein intake matters for keeping muscle while you lose fat.
- Resistance exercise helps preserve muscle and physical function during weight loss.
- Poor sleep and high stress can both increase appetite.
- Some medical conditions, such as an underactive thyroid, can affect weight, and a provider may check for them with a blood test when weight changes unexpectedly.
Whether to continue, change or stop treatment is a decision for you and your prescribing provider. You should not change how you take the medication on your own.
When to contact your provider promptly
Contact your provider if you are regaining weight while still taking the medication, if your appetite returns suddenly, or if you develop new symptoms such as severe abdominal pain, persistent vomiting or signs of dehydration. These situations call for an evaluation rather than continued observation.
Where Truthe fits
If you and a licensed provider decide that a GLP-1 medication belongs in your plan, the Truthe Rx LEAN program is a physician-prescribed weight-loss program for adults that offers semaglutide or tirzepatide and includes regular check-ins with your provider. Truthe does not prescribe, and an independent licensed provider decides whether a prescription is appropriate for you.
Disclaimer: This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, changing or stopping any medication.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID 33567185. doi.org/10.1056/NEJMoa2032183
- Elmendorf AJ, Douros JD, Knerr PJ, Flak JN. Improving incretin-mediated body weight loss via energy expenditure. Trends Endocrinol Metab. 2026;37(8):764-774. PMID 41904104. doi.org/10.1016/j.tem.2025.12.004
- Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. PMID 22029981. doi.org/10.1056/NEJMoa1105816
- Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565. PMID 21430088. doi.org/10.2337/db10-0474
Ready to Start?
Explore personalized treatment plans designed around your goals. Every plan is supported by licensed providers and premium compounding pharmacies.
